

Second primary malignancy in multiple myeloma: does a prior malignancy matter?

Authors

Alissa Visram,¹ Hsien Seow,¹ Rajeshkar Chakraborty,² Gregory Pond,¹ Ana Gayowsky,³ Ghulam Rehman Mohyuddin,⁴ Samer Al Hadidi,⁵⁻⁷ Doris K. Hansen,⁸ Surbhi Sidana,⁹ Rohan Gouda,¹ Alejandro Garcia-Horton,¹ Rafael Fonseca⁸ and Hira Mian¹

¹Department of Oncology, McMaster University, Hamilton, Canada;

²Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA; ³Institute for Clinical Evaluative Sciences, McMaster University, Hamilton, Canada;

⁴Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; ⁵Department of Hematology and Oncology, Simmons

Comprehensive Cancer Center, Dallas, TX, USA; ⁶Southwestern Medical Center, Dallas, TX, USA; ⁷Division of Hematology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA; ⁸H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA and ⁹Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, USA

Correspondence:

ALISSA VISRAM - visrama@hhsc.ca

<https://doi.org/10.3324/haematol.2025.300320>

Table S1. Univariate and multivariate landmark model results to identify factors associated with SPM risk with death as a competing risk

Landmark Timeframe	Variable	N	Univariate Results (sHR, 95% CI)				Multivariate Results (sHR, 95% CI)			
			sHR	Lower	Upper	P-Value	sHR	Lower	Upper	P-Value
12 months	Prior malignancy (pre-MM diagnosis)	10424	1.226	1.031	1.458	0.0211	1.284	1.073	1.536	0.0062
	Age		0.995	0.990	1.000	0.0335	1.004	0.997	1.012	0.2620
	Male sex		1.297	1.132	1.486	0.0002	1.278	1.115	1.465	0.0004
	Diagnosis year 2011-2014		1.142	0.950	1.372	0.1579	1.120	0.932	1.347	0.2275
	Diagnosis year 2015-2018		1.247	1.042	1.493	0.0163	1.215	1.002	1.473	0.0475
	Diagnosis year 2019-2022		1.011	0.802	1.274	0.9262	1.021	0.793	1.315	0.8723
	<6 months of lenalidomide within 12 months post diagnosis		1.177	0.995	1.393	0.0576	1.025	0.853	1.231	0.7911
	6+ months of lenalidomide within 12 months post diagnosis		0.806	0.637	1.019	0.0712	0.840	0.652	1.082	0.1774
	ASCT within 12 months post diagnosis		1.353	1.185	1.545	<.0001	1.444	1.195	1.744	0.0001
18 months	Prior malignancy (pre-MM diagnosis)	9594	1.258	1.048	1.511	0.0138	1.333	1.104	1.610	0.0029
	Age		0.994	0.989	1.000	0.0348	1.005	0.996	1.013	0.2727
	Male sex		1.280	1.110	1.476	0.0007	1.256	1.089	1.450	0.0018
	Diagnosis year 2011-2014		1.126	0.931	1.363	0.2212	1.107	0.913	1.342	0.3011
	Diagnosis year 2015-2018		1.240	1.028	1.495	0.0243	1.146	0.930	1.413	0.2014
	Diagnosis year 2019-2022		1.062	0.824	1.369	0.6416	0.963	0.727	1.276	0.7934
	<6 months of lenalidomide within 18 months post diagnosis		1.003	0.795	1.265	0.9813	0.918	0.724	1.165	0.4817
	6+ months of lenalidomide within 18 months post diagnosis		1.240	1.061	1.448	0.0068	1.150	0.961	1.377	0.1275
	ASCT within 18 months post diagnosis		1.372	1.194	1.577	<.0001	1.508	1.230	1.848	<.0001
24 months	Prior malignancy (pre-MM diagnosis)	8906	1.315	1.087	1.592	0.0049	1.392	1.143	1.695	0.0010
	Age		0.993	0.987	0.998	0.0086	1.002	0.994	1.011	0.5758
	Male sex		1.299	1.119	1.507	0.0006	1.270	1.093	1.475	0.0018
	Diagnosis year 2011-2014		1.144	0.939	1.393	0.1820	1.148	0.939	1.402	0.1776
	Diagnosis year 2015-2018		1.256	1.034	1.525	0.0215	1.216	0.979	1.510	0.0767
	Diagnosis year 2019-2022		1.130	0.857	1.492	0.3857	1.090	0.808	1.472	0.5726
	<6 months of lenalidomide within 24 months post diagnosis		0.660	0.490	0.890	0.0065	0.638	0.471	0.865	0.0038
	6+ months of lenalidomide within 24 months post diagnosis		1.177	1.011	1.371	0.0356	1.056	0.889	1.253	0.5371
	ASCT within 24 months post diagnosis		1.398	1.209	1.618	<.0001	1.488	1.204	1.838	0.0002
30 months	Prior malignancy (pre-MM diagnosis)	8265	1.298	1.058	1.593	0.0125	1.390	1.126	1.716	0.0022

Age	0.993	0.988	0.999	0.0205	1.005	0.996	1.015	0.2433
Male sex	1.260	1.077	1.474	0.0039	1.233	1.053	1.444	0.0093
Diagnosis year 2011-2014	1.135	0.923	1.394	0.2298	1.126	0.912	1.390	0.2687
Diagnosis year 2015-2018	1.275	1.040	1.563	0.0194	1.213	0.968	1.520	0.0935
Diagnosis year 2019-2022	1.362	1.004	1.847	0.0470	1.286	0.926	1.784	0.1328
<6 months of lenalidomide within 30 months post diagnosis	0.704	0.515	0.964	0.0284	0.677	0.493	0.931	0.0162
6+ months of lenalidomide within 30 months post diagnosis	1.186	1.014	1.388	0.0328	1.053	0.885	1.253	0.5576
ASCT within 30 months post diagnosis	1.461	1.252	1.706	<.0001	1.634	1.309	2.041	<.0001